Advances in Cancer Treatment: Harnessing Antibody-Drug Conjugates and Oncolytic Viruses for Targeted Therapy

Effective cancer treatment remains a major challenge due to its heterogeneity and complexity. However, emerging therapies such as antibody-drug conjugates (ADCs) and oncolytic viruses show great potential in leveraging the body's natural defenses to selectively target and destroy cancer cells. These promising treatments have demonstrated encouraging results in clinical trials, and ongoing research and development are expected to further enhance their efficacy and improve patient outcomes.